These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
127 related articles for article (PubMed ID: 32006091)
1. Persistence, effectiveness and safety of dabigatran in "real-world" Chinese patients with nonvalvular atrial fibrillation. Rong G; Huang Y; Wang L; Liang H; Wang H Heart Vessels; 2020 Jul; 35(7):977-984. PubMed ID: 32006091 [TBL] [Abstract][Full Text] [Related]
2. Effectiveness and safety of dabigatran therapy in daily-care patients with atrial fibrillation. Results from the Dresden NOAC Registry. Beyer-Westendorf J; Ebertz F; Förster K; Gelbricht V; Michalski F; Köhler C; Werth S; Endig H; Pannach S; Tittl L; Sahin K; Daschkow K; Weiss N Thromb Haemost; 2015 Jun; 113(6):1247-57. PubMed ID: 25739533 [TBL] [Abstract][Full Text] [Related]
3. Comparison of dabigatran, rivaroxaban, and apixaban for effectiveness and safety in atrial fibrillation: a nationwide cohort study. Rutherford OW; Jonasson C; Ghanima W; Söderdahl F; Halvorsen S Eur Heart J Cardiovasc Pharmacother; 2020 Apr; 6(2):75-85. PubMed ID: 31942972 [TBL] [Abstract][Full Text] [Related]
4. Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Previous Stroke or Transient Ischemic Attack. Coleman CI; Peacock WF; Bunz TJ; Alberts MJ Stroke; 2017 Aug; 48(8):2142-2149. PubMed ID: 28655814 [TBL] [Abstract][Full Text] [Related]
5. Dabigatran for Japanese Patients with Atrial Fibrillation and Prior Stroke: A Subgroup Analysis of the J-Dabigatran Surveillance Program. Yasaka M; Uchiyama S; Atarashi H; Okumura K; Koretsune Y; Yamashita T; Taniguchi A; Fukaya T; Inoue H; J Stroke Cerebrovasc Dis; 2020 May; 29(5):104717. PubMed ID: 32113736 [TBL] [Abstract][Full Text] [Related]
6. The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study. Connolly SJ; Wallentin L; Ezekowitz MD; Eikelboom J; Oldgren J; Reilly PA; Brueckmann M; Pogue J; Alings M; Amerena JV; Avezum A; Baumgartner I; Budaj AJ; Chen JH; Dans AL; Darius H; Di Pasquale G; Ferreira J; Flaker GC; Flather MD; Franzosi MG; Golitsyn SP; Halon DA; Heidbuchel H; Hohnloser SH; Huber K; Jansky P; Kamensky G; Keltai M; Kim SS; Lau CP; Le Heuzey JY; Lewis BS; Liu L; Nanas J; Omar R; Pais P; Pedersen KE; Piegas LS; Raev D; Smith PJ; Talajic M; Tan RS; Tanomsup S; Toivonen L; Vinereanu D; Xavier D; Zhu J; Wang SQ; Duffy CO; Themeles E; Yusuf S Circulation; 2013 Jul; 128(3):237-43. PubMed ID: 23770747 [TBL] [Abstract][Full Text] [Related]
7. Direct comparative effectiveness and safety between non-vitamin K antagonist oral anticoagulants for stroke prevention in nonvalvular atrial fibrillation: a systematic review and meta-analysis of observational studies. Li G; Lip GYH; Holbrook A; Chang Y; Larsen TB; Sun X; Tang J; Mbuagbaw L; Witt DM; Crowther M; Thabane L; Levine MAH Eur J Epidemiol; 2019 Feb; 34(2):173-190. PubMed ID: 29948370 [TBL] [Abstract][Full Text] [Related]
8. Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation. Yao X; Abraham NS; Sangaralingham LR; Bellolio MF; McBane RD; Shah ND; Noseworthy PA J Am Heart Assoc; 2016 Jun; 5(6):. PubMed ID: 27412905 [TBL] [Abstract][Full Text] [Related]
9. Sex-Specific Comparative Effectiveness of Oral Anticoagulants in Elderly Patients With Newly Diagnosed Atrial Fibrillation. Palamaner Subash Shantha G; Bhave PD; Girotra S; Hodgson-Zingman D; Mazur A; Giudici M; Chrischilles E; Vaughan Sarrazin MS Circ Cardiovasc Qual Outcomes; 2017 Apr; 10(4):. PubMed ID: 28408716 [TBL] [Abstract][Full Text] [Related]
10. Dabigatran in nonvalvular atrial fibrillation: from clinical trials to real-life experience. Mumoli N; Mastroiacovo D; Tamborini-Permunian E; Vitale J; Giorgi-Pierfranceschi M; Cei M; Dentali F J Cardiovasc Med (Hagerstown); 2017 Jul; 18(7):467-477. PubMed ID: 28509761 [TBL] [Abstract][Full Text] [Related]
11. Individual Treatment Effect Estimation of 2 Doses of Dabigatran on Stroke and Major Bleeding in Atrial Fibrillation. Stam-Slob MC; Connolly SJ; van der Graaf Y; van der Leeuw J; Dorresteijn JAN; Eikelboom JW; Peters RJG; Alings M; Visseren FLJ Circulation; 2019 Jun; 139(25):2846-2856. PubMed ID: 31046423 [TBL] [Abstract][Full Text] [Related]
12. Safety and effectiveness of non-vitamin K oral anticoagulants versus warfarin in real-world patients with non-valvular atrial fibrillation: a retrospective analysis of contemporary Japanese administrative claims data. Kohsaka S; Katada J; Saito K; Jenkins A; Li B; Mardekian J; Terayama Y Open Heart; 2020; 7(1):e001232. PubMed ID: 32341789 [TBL] [Abstract][Full Text] [Related]
13. Effectiveness and safety of dabigatran versus acenocoumarol in 'real-world' patients with atrial fibrillation. Korenstra J; Wijtvliet EP; Veeger NJ; Geluk CA; Bartels GL; Posma JL; Piersma-Wichers M; Van Gelder IC; Rienstra M; Tieleman RG Europace; 2016 Sep; 18(9):1319-27. PubMed ID: 26843571 [TBL] [Abstract][Full Text] [Related]
14. Comparison of the Effectiveness and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Newly Diagnosed Atrial Fibrillation. Hernandez I; Zhang Y; Saba S Am J Cardiol; 2017 Nov; 120(10):1813-1819. PubMed ID: 28864318 [TBL] [Abstract][Full Text] [Related]
15. Characterizing major bleeding in patients with nonvalvular atrial fibrillation: a pharmacovigilance study of 27 467 patients taking rivaroxaban. Tamayo S; Frank Peacock W; Patel M; Sicignano N; Hopf KP; Fields LE; Sarich T; Wu S; Yannicelli D; Yuan Z Clin Cardiol; 2015 Feb; 38(2):63-8. PubMed ID: 25588595 [TBL] [Abstract][Full Text] [Related]
16. Effectiveness and safety of long-term dabigatran among patients with non-valvular atrial fibrillation in clinical practice: J-dabigatran surveillance. Inoue H; Uchiyama S; Atarashi H; Okumura K; Koretsune Y; Yasaka M; Yamashita T; Taniguchi A; Fukaya T; J Cardiol; 2019 Jun; 73(6):507-514. PubMed ID: 30737182 [TBL] [Abstract][Full Text] [Related]
17. Real Data on Effectiveness, Tolerability and Safety of New Oral Anticoagulant Agents: Focus on Dabigatran. Stabile E; Izzo R; Rozza F; Losi MA; Coscioni E; Trimarco B High Blood Press Cardiovasc Prev; 2016 Jun; 23(2):115-22. PubMed ID: 27207360 [TBL] [Abstract][Full Text] [Related]
18. Comparative safety and effectiveness of dabigatran vs. rivaroxaban and apixaban in patients with non-valvular atrial fibrillation: a retrospective study from a large healthcare system. Villines TC; Ahmad A; Petrini M; Tang W; Evans A; Rush T; Thompson D; Oh K; Schwartzman E Eur Heart J Cardiovasc Pharmacother; 2019 Apr; 5(2):80-90. PubMed ID: 30500885 [TBL] [Abstract][Full Text] [Related]
19. Dabigatran Versus Warfarin for Atrial Fibrillation in Real-World Clinical Practice: A Systematic Review and Meta-Analysis. Romanelli RJ; Nolting L; Dolginsky M; Kym E; Orrico KB Circ Cardiovasc Qual Outcomes; 2016 Mar; 9(2):126-34. PubMed ID: 26812933 [TBL] [Abstract][Full Text] [Related]
20. Oral anticoagulants usage in Japanese patients aged 18-74 years with non-valvular atrial fibrillation: a retrospective analysis based on insurance claims data. Ohshima A; Koyama T; Ogawa A; Zamami Y; Tanaka HY; Kitamura Y; Sendo T; Hinotsu S; Miller MW; Kano MR Fam Pract; 2019 Nov; 36(6):685-692. PubMed ID: 31329899 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]